JNJs talc powder Thema hat ja auch >11.000 Klagen anhängig.
Weitere Parallelen sind ja auch noch ein bißchen vorhanden: Pharma Konzern, Krebsverdacht.
SSD schrieb 12/2018 zu JNJ, wo bei mir die Frage aufpoppt, weshalb bei Bayer solch hohe Forderungen pro Fall im Raum stehen?
"... With 11,700 claims against the company, it's hard to say where J&J's potential settlement would fall on this spectrum. However, whether one looks at just drug-related lawsuits or settlements across all types of companies, almost all of the biggest suits ended with less than $5 billion in damages.
While the number of claims against J&J could rise, for now let's assume the company decides to settle all 11,700 cases for $1 million each. Wells Fargo analyst Larry Biegelsen wrote a note to clients stating the highest per-case settlement the firm has seen was $280,000 each, so using $1 million seems quite conservative.
In that scenario, Johnson & Johnson would be on the hook for $11.7 billion, the fourth largest settlement of all time (and the largest drug settlement by more than $8 billion).
Could the firm afford to make such a payout without jeopardizing its dividend?
It certainly looks like it. Through the first nine months of 2018, Johnson & Johnson generated about $16 billion in operating cash flow and spent $2.4 billion on capital expenditures, leaving $13.6 billion in free cash flow, which funds the dividend ...... "
Weitere Parallelen sind ja auch noch ein bißchen vorhanden: Pharma Konzern, Krebsverdacht.
SSD schrieb 12/2018 zu JNJ, wo bei mir die Frage aufpoppt, weshalb bei Bayer solch hohe Forderungen pro Fall im Raum stehen?
"... With 11,700 claims against the company, it's hard to say where J&J's potential settlement would fall on this spectrum. However, whether one looks at just drug-related lawsuits or settlements across all types of companies, almost all of the biggest suits ended with less than $5 billion in damages.
While the number of claims against J&J could rise, for now let's assume the company decides to settle all 11,700 cases for $1 million each. Wells Fargo analyst Larry Biegelsen wrote a note to clients stating the highest per-case settlement the firm has seen was $280,000 each, so using $1 million seems quite conservative.
In that scenario, Johnson & Johnson would be on the hook for $11.7 billion, the fourth largest settlement of all time (and the largest drug settlement by more than $8 billion).
Could the firm afford to make such a payout without jeopardizing its dividend?
It certainly looks like it. Through the first nine months of 2018, Johnson & Johnson generated about $16 billion in operating cash flow and spent $2.4 billion on capital expenditures, leaving $13.6 billion in free cash flow, which funds the dividend ...... "
